been development positive have on There clinical the Brian. you, and business multiple fronts. regulatory Thank developments
we payments and $X future receive terms and For Development achieved. milestones the if the with an million July, East XX Africa and countries. of Middle and CIS, license to Under received up million a in we successfully this BD aggregate Turkey, front agreement sales COPIKTRA $XX exclusive total a and Commercialize an for partnership the to ex-U.S. upfront new agreement, we're of of are strategic Sanofi development to of executed in certain payment eligible Russia
in royalties eligible COPIKTRA territories. future based on also of double-digit to receive sales We're net the licensed percentage
regulatory to FL year. and in approval front, planning CLL/SLL relapsed end with to the we're a refractory or the Agency of seeking duvelisib the by marketing submit Medicines authorization patients application On the for European
its is however, orphan the characterize further the registration-directed or in and currently lymphoma treatment of study efficacy T-cell aggressive received patients Duvelisib drug in with X for T-cell relapsed this lymphoma, from lymphoma. tolerability not an refractory use of for Phase treatment of designation we're recently the the conducting approved FDA Duvelisib currently in T-cell PRIMO to type lymphoma, population.
and directed portion ongoing was year data of presentation study Japan. U.S., this in in of be of Europe the the for to the registration The The the PRIMO Hematology meeting the we American and annual dose-selection is dose-optimization, and conducted study currently at XXXX December. upcoming submitted Society portion completed is earlier PRIMO
made Yakult early COPIKTRA first with patients progress or Honsha primary one dosed enroll is our the recently also Phase In We CLL/SLL in evaluating partners. at in October, prior Japanese the to duvelisib study, Their with Xb objective of and Phase a patient study global study Xb response endpoint expected rate. bridging least refractory XX following multicenter open-level therapy. approximately the patients is relapsed
the DUO if study basis study results study are study based to COPIKTRA of of expected on bridging overall a for the survival as efficacy serve bridging Yakult's X submission is Verastem regulatory the of relapsed endpoints or in progression-free and treatment survival, Phase a to the successful, study form for Secondary include and expected refractory observed the in safety. Japan. safety and of CLL/SLL This Oncology's
and development collaborators first Also meetings. at early and medical on by XXXX. presenting have generating currently in end quarter, dubelisib of been We the patient dose their fourth Throughout duvelisib expect data supportive in the the to partnered bridging part is with global study Verastem front, external and the quarter CSPC CSPC its actively Group Pharmaceutical to China. the third of
Oncology Chronic abstracts medical Workshop Society presented of Lymphocytic of the and Hematologic Annual at seven the XXXX Annual were A duvelisib Leukemia meetings, two oncology total Meeting. on XXth International
the hoc analysis a X refractory effect of data continue clinical data Phase post patients high evaluating X the of of Phase with wide DYNAMO with data and including on DUO a patients abstracts or on ongoing study, study COPIKTRA. including from lymphocytosis, to from with presented the zone range refractory the Collectively These duvelisib Phase data marginal highlighted from with dose modification COPIKTRA data study X DUO patients support lymphoma. data the in risk from factors development relapsed presented CLL/SLL, the
on And Fifth inhibitor presented finally, presented in Concepts Lymphoid cell showed research the dual PIXK-delta models duvelisib, of The the inhibitor activity lymphoma. Malignancies. Conference compared anticancer preclinical the of was to data at idelalisib superior mantle in New important preclinical PIXK-delta/gamma International
these lymphoid malignancy with is data study indications and through development the As support we our expand duvelisib to of goal patients stated in trials into long-term previously, preclinical clinical MCL. additional duvelisib future
studies. initiation lymphoma, response will and company-sponsored named Phase evaluate relapsed least studies, dosing which be the addition on working patients intermittent In randomized study, at to X effect tumor three safety also will open-label and towards these with holidays we’re TEMPO ongoing non-Hodgkin one therapy. is One systemic dosing indolent of of in refractory prior who've X-week planned or received
medical the on build of data during this study, end to the We at therapy interruptions received recently presented dose that on this is will commence effects previously effective of means this and are impacting by XXX IRB efficacy. which study year. show approximately patients patients meetings enroll and keeping an expected managing multicenter approval that of is side purpose without for The to
the the clinic second for will in effect duvelisib's study duvelisib of PD-X this and look The cell Phase with carcinoma. the by dual inhibitor the pembrolizumab immunomodulatory this The preclinical end rationale year. squamous of research study head this is provides in We this inhibition patients combine PIXK neck commence with further to was in combination. effects seen of previously which study, forward to a exploring that IbX expect and combination we the
FDA into end accelerated in we're full III converting in We're the by DUO COPIKTRA study the with of confirmatory year. approval and study the aimed phase Phase to expect on the final third, we commence details the for final And FL at working approval. preparation of this
to to the turn I'd Now like call financials. the for Rob over
